Metformin for Second-Generation Antipsychotic-Induced Weight Gain in Youth: A Review of Current Evidence
Abstract
Second-generation antipsychotics are widely used to treat a range of psychiatric disorders in children and adolescents but are frequently associated with significant weight gain and metabolic sequelae. Metformin, an antihyperglycemic agent, is an evidence-based option for mitigating these adverse effects in youth. Despite evidence supporting its efficacy and safety, adjunctive metformin remains underutilized in pediatric patients receiving second-generation antipsychotics.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.